多发性骨髓瘤患者血小板内及尿液中转化生长因子-β水平升高。

Increased intraplatelet and urinary transforming growth factor-beta in patients with multiple myeloma.

作者信息

Jiang X, Kanai H, Hiromura K, Sawamura M, Yano S

机构信息

Third Department of Internal Medicine, Gumma University School of Medicine, Maebashi, Japan.

出版信息

Acta Haematol. 1995;94(1):1-6. doi: 10.1159/000203962.

DOI:10.1159/000203962

PMID:7653206

Abstract

The concentrations of transforming growth factor-beta (TGF-beta) in platelets, plasma and urine from 27 patients with multiple myeloma (MM) and from 22 normal controls were measured by sandwich enzyme-linked immunosorbent assay using a monoclonal antibody specific for human TGF-beta 1+2+3. A significantly increased intraplatelet TGF-beta (24.6 +/- 9.6 vs. 17.8 +/- 8.8 ng/10(5) platelets, p < 0.01) and urinary TGF-beta (1.4 +/- 0.8 vs 1.0 +/- 0.4 ng/mg Cr, p < 0.02) were observed in MM patients compared with normal controls. The mean platelet TGF-beta level in MM patients with osteolytic lesions was more increased than in those without osteolytic lesions (29.6 +/- 7.7 vs 18.4 +/- 8.2 ng/10(5) platelets, p < 0.001). In this study, we evaluated the possible role of TGF-beta in the pathogenesis of myeloma, especially in osteolytic lesions.

摘要

采用针对人转化生长因子β1+2+3的单克隆抗体，通过夹心酶联免疫吸附测定法，检测了27例多发性骨髓瘤（MM）患者及22例正常对照者血小板、血浆和尿液中转化生长因子β（TGF-β）的浓度。与正常对照相比，MM患者血小板内TGF-β（24.6±9.6对17.8±8.8 ng/10⁵血小板，p<0.01）及尿TGF-β（1.4±0.8对1.0±0.4 ng/mg肌酐，p<0.02）显著升高。有溶骨性病变的MM患者血小板TGF-β平均水平比无溶骨性病变者升高更明显（29.6±7.7对18.4±8.2 ng/10⁵血小板，p<0.001）。在本研究中，我们评估了TGF-β在骨髓瘤发病机制中，尤其是在溶骨性病变中的可能作用。